The mental faculties a biotech CEO needs most are the first to degrade under chronic pressure. This is not a character issue, ...

Patent attorney Eric M. Brusca, Ph.D., explains how biopharmaceutical companies and their IP law firms can cultivate ...

Life Science Cares, an industry philanthropic organization, turns 10 in April. Now in five cities and Switzerland, the organization remains focused on fighting poverty.

Life sciences startups have long felt the gravitational pull of Boston and San Francisco when looking to raise capital, expand, and recruit talent. These two coastal regions, with an established ...

At a time of continuous change and increasing complexity, success for life sciences companies will largely depend on how they support, nurture and develop their teams. But even that has gotten more ...

For many families living with rare pediatric diseases, hope often arrives quietly — after years of uncertainty, missed diagnoses, and being told that treatment may never come in time. For Lindsey ...

Each January, the J.P. Morgan Healthcare Conference helps to set the biopharmaceutical industry agenda for the coming year, and more suits can be seen on the streets of San Francisco than during any ...

Here’s my thesis: biotech remains one of the most exciting and promising industries in the world, driven by the inescapable reality that nothing matters more than our health. Despite the fact that in ...

Royalty-bearing license agreements are a cornerstone of commercialization in the life sciences and technology industries. Companies often use them to expand their business into new markets while ...

The well-worn adage “good companies are bought, not sold” suggests that top-tier businesses, especially in high-growth industries like life sciences, do not need to seek buyers; instead, buyers pursue ...

Since the start of his second term, President Trump has shown a clear commitment to improving access to medicines for American patients. In late September 2025, his Administration reaffirmed this ...